Work

Phosphoglycerate kinase 1 as a therapeutic target in neurological disease

Year: 2025

Type: review

Abstract: Phosphoglycerate kinase 1 (PGK1) is a highly conserved enzyme that catalyzes the initial ATP-producing step in glycolysis. Improving cellular energy production by increasing PGK1 activity may be beneficial in multiple neurological conditions where cell metabolism is dysregulated, including Parkinson's disease (PD) and motor neuron disease (MND). This review examines recent evidence that suggests increasing PGK1 activity may be beneficial in multiple neurological conditions and discusses the current challenges surrounding the development of PGK1-focused therapies. PGK1 has considerable therapeutic potential, but novel PGK1 activators are needed to maximize the benefit for patients.

Source: Trends in Molecular Medicine

DOI: 10.1016/j.molmed.2025.03.008

Authors: Harriet McHale-Owen, Kiterie M.E. Faller, Helena Chaytow, Thomas H. Gillingwater

Institutions: Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $7,030